Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Dunlop

Showing results (81-90 of 99) with videos related to

Pageof 10
Sort By:
Psychopharmacology|June 7, 2011
Preclinical assessment of an adjunctive treatment approach for cognitive impairment associated with schizophrenia using the alpha7 nicotinic acetylcholine receptor agonist WYE-103914/SEN34625Karen L Marquis, Thomas A Comery, Flora Jow, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 16, 2011
Characterization of vabicaserin (SCA-136), a selective 5-hydroxytryptamine 2C receptor agonistJohn Dunlop, Stephanie W Watts, James E Barrett, et al.
The European Journal of Neuroscience|July 20, 2005
Role of the GLT-1 subtype of glutamate transporter in glutamate homeostasis: the GLT-1-preferring inhibitor WAY-855 produces marginal neurotoxicity in the rat hippocampusJulie V Selkirk, Lisa M Nottebaum, Alicia M Vana, et al.
Plos One|August 13, 2013
Behavioral characterization of A53T mice reveals early and late stage deficits related to Parkinson's diseaseKatrina L Paumier, Stacey J Sukoff Rizzo, Zdenek Berger, et al.
BMJ Open|August 3, 2024
Implementation of time-limited parenteral hydromorphone in people with treatment-resistant injecting opioid use disorder: a protocol for a single-site, uncontrolled, open-label study to assess feasibility, safety and costCraig Rodgers, Krista J Siefried, Alison Ritter, et al.
Neurobiology of Disease|July 9, 2008
Amiloride is neuroprotective in an MPTP model of Parkinson's diseaseRobert L Arias, Mei-Li A Sung, Dmytro Vasylyev, et al.
Journal of Medicinal Chemistry|October 23, 2012
N-[5-(5-fluoropyridin-3-yl)-1H-pyrazol-3-yl]-4-piperidin-1-ylbutyramide (SEN78702, WYE-308775): a medicinal chemistry effort toward an α7 nicotinic acetylcholine receptor agonist preclinical candidateRiccardo Zanaletti, Laura Bettinetti, Cristiana Castaldo, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|May 29, 2015
Selective inhibition of KCC2 leads to hyperexcitability and epileptiform discharges in hippocampal slices and in vivoSudhir Sivakumaran, Ross A Cardarelli, Jamie Maguire, et al.
Annals of Neurology|August 29, 2014
Prioritized research recommendations from the National Institute of Neurological Disorders and Stroke Parkinson's Disease 2014 conferenceBeth-Anne Sieber, Story Landis, Walter Koroshetz, et al.
Neuropharmacology|December 1, 2015
State-dependent alterations in sleep/wake architecture elicited by the M4 PAM VU0467154 - Relation to antipsychotic-like drug effectsRobert W Gould, Michael T Nedelcovych, Xuewen Gong, et al.
Pageof 10

Showing results (81-90 of 99) with videos related to

Sort By:
Pageof 10
Psychopharmacology|June 7, 2011
Preclinical assessment of an adjunctive treatment approach for cognitive impairment associated with schizophrenia using the alpha7 nicotinic acetylcholine receptor agonist WYE-103914/SEN34625Karen L Marquis, Thomas A Comery, Flora Jow, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 16, 2011
Characterization of vabicaserin (SCA-136), a selective 5-hydroxytryptamine 2C receptor agonistJohn Dunlop, Stephanie W Watts, James E Barrett, et al.
The European Journal of Neuroscience|July 20, 2005
Role of the GLT-1 subtype of glutamate transporter in glutamate homeostasis: the GLT-1-preferring inhibitor WAY-855 produces marginal neurotoxicity in the rat hippocampusJulie V Selkirk, Lisa M Nottebaum, Alicia M Vana, et al.
Plos One|August 13, 2013
Behavioral characterization of A53T mice reveals early and late stage deficits related to Parkinson's diseaseKatrina L Paumier, Stacey J Sukoff Rizzo, Zdenek Berger, et al.
BMJ Open|August 3, 2024
Implementation of time-limited parenteral hydromorphone in people with treatment-resistant injecting opioid use disorder: a protocol for a single-site, uncontrolled, open-label study to assess feasibility, safety and costCraig Rodgers, Krista J Siefried, Alison Ritter, et al.
Neurobiology of Disease|July 9, 2008
Amiloride is neuroprotective in an MPTP model of Parkinson's diseaseRobert L Arias, Mei-Li A Sung, Dmytro Vasylyev, et al.
Journal of Medicinal Chemistry|October 23, 2012
N-[5-(5-fluoropyridin-3-yl)-1H-pyrazol-3-yl]-4-piperidin-1-ylbutyramide (SEN78702, WYE-308775): a medicinal chemistry effort toward an α7 nicotinic acetylcholine receptor agonist preclinical candidateRiccardo Zanaletti, Laura Bettinetti, Cristiana Castaldo, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|May 29, 2015
Selective inhibition of KCC2 leads to hyperexcitability and epileptiform discharges in hippocampal slices and in vivoSudhir Sivakumaran, Ross A Cardarelli, Jamie Maguire, et al.
Annals of Neurology|August 29, 2014
Prioritized research recommendations from the National Institute of Neurological Disorders and Stroke Parkinson's Disease 2014 conferenceBeth-Anne Sieber, Story Landis, Walter Koroshetz, et al.
Neuropharmacology|December 1, 2015
State-dependent alterations in sleep/wake architecture elicited by the M4 PAM VU0467154 - Relation to antipsychotic-like drug effectsRobert W Gould, Michael T Nedelcovych, Xuewen Gong, et al.
Pageof 10